AI Market Mood: Stock Dashboard
XAIR
Fundamental
Company: Beyond Air Inc
Sector: Healthcare
Industry: Medical Devices
Country: USA
Exchange: NASD
Index: -
P/E: -
EPS (ttm): -5.42
Insider Own: 5.88%
Shs Outstand: 10.53M
Perf Week: -8.01%
Market Cap: 7.82M
Forward P/E: -
EPS next Y: -1.75
Insider Trans: 0.00%
Shs Float: 9.91M
Perf Month: -23.86%
Enterprise Value: 13.73M
PEG: -
EPS next Q: -0.54
Inst Own: 13.95%
Short Float: 1.15%
Perf Quarter: -19.38%
Income: -31.00M
P/S: 1.13
EPS this Y: 72.16%
Inst Trans: -1.13%
Short Ratio: 0.01
Perf Half Y: -67.86%
Sales: 6.92M
P/B: 0.77
EPS next Y Percentage: 54.47%
ROA: -87.43%
Short Interest: 0.11M
Perf YTD: 2.25%
Book/sh: 0.97
P/C: 0.44
EPS next 5Y: 51.60%
ROE: -240.75%
52W High: 6.39 -88.39%
Perf Year: -87.32%
Cash/sh: 1.69
P/FCF: -
EPS past 3/5Y: 25.75% 17.29%
ROIC: -99.00%
52W Low: 0.67 10.26%
Perf 3Y: -99.40%
Dividend Est.: -
EV/EBITDA: -
Sales past 3/5Y: - 21.66%
Gross Margin: 1.83%
Volatility W: 7.43%
Volatility M: 8.06%
Perf 5Y: -99.30%
Dividend TTM: -
EV/Sales: 1.98
EPS Y/Y TTM: 74.30%
Oper. Margin: -419.51%
ATR (14): 0.08
Perf 10Y: -
Dividend Ex-Date: -
Quick Ratio: 4.77
Sales Y/Y TTM: 129.04%
Profit Margin: -447.75%
RSI (14): 33.20
Recom: 1.40
Dividend Gr. 3/5Y: - -
Current Ratio: 5.12
EPS Q/Q: 71.23%
SMA20: -10.59%
Beta: 0.50
Target Price: 7.75
Payout: -
Debt/Eq: 2.91
Sales Q/Q: 104.66%
SMA50: -33.56%
Rel Volume: 0.01
Prev Close: 0.75
Employees: 61
LT Debt/Eq: 2.86
Earnings: Feb 13 BMO
SMA200: -63.05%
Avg Volume: 7.66M
Price: 0.74
IPO: Sep 23, 2016
Option/Short: No / Yes
EPS/Sales Surpr.: -13.26% 1.89%
Trades:
Volume: 94,037
Change: -0.76%
Technical:
Latest News:
New AI drug discovery powerhouse Xaira rises with $1B in funding - Fierce Biotech very bullish
XAIR
Summary: Xaira Therapeutics has emerged with $1 billion in committed funding and an impressive team led by prominent figures in the biotech industry, including Marc Tessier-Lavigne, Ph.D., and David Baker, Ph.D. The company aims to revolutionize drug discovery by combining machine learning, data generation, and therapeutic product development.
Full article2024-04-24T14:00:06Z